SGLT2 and DPP4 inhibition: Extending from glycaemic control to kidney protection – D.Z. Cherney, Canada
Results of the DELIGHT trial: effects of dapagliflozin and saxagliptin on renal outcomes – C. Pollock, Australia
Commentator: M.A. Nauck, Germany
Q&A with all speakers



































Todos os direitos reservados